About: Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.77 (+12.42%)
SKYE NASDAQ Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc. Common Stock share price
SKYE price activity
Last Price
$1.770
Change (24hr)
0.20 USD (12.42%)
Volume
97.63K
Volume (4w avg)
-
Open
$1.65
Day Range
$1.65 - $1.89
Previous Close
$1.57
Last Trade
18 Sep, 8:00 pm GMT+0
Delayed
18 Sep, 8:00 pm GMT+0
SKYE price performance
Delayed
18 Sep, 8:00 pm GMT+0
SKYE Market Signals